Accelus develops expandable spinal implant technologies and markets a portfolio of implants and instruments for minimally invasive spine surgery. Its products include the FlareHawk Interbody Fusion System with Adaptive Geometry technology, the LineSider Spinal System with modular-cortical screws, and the Toro-L Interbody Fusion System. The company designs implants and instruments for a range of techniques across hospital and ambulatory surgery center settings. Accelus reports more than 32,000 cages implanted in 25 countries, which the company cites as a foundation for growth. The new equity financing will support continued commercial expansion, deepen U.S. market presence, and fund pipeline innovation, including expansion of the FlareHawk and Toro portfolios. In conjunction with the financing, Accelus appointed industry veteran Bernie Haffey as chairman of the board to help oversee the next phase of growth. Accelus develops expandable interbody fusion implants, including its flagship FlareHawk and Toro systems, and emphasizes Adaptive Geometry™ technology for better endplate conformity. The company positions itself as a worldwide leader in expandable spinal implant solutions and targets multiple surgical approaches (TLIF, PLIF, endoscopic-assisted, percutaneous, and lateral). Accelus plans to expand its sales force into underpenetrated markets and to accelerate clinical research and product development around its core implants. The firm is pursuing additional clinical studies and data collection to reinforce the clinical efficacy of FlareHawk, which prior reports have linked to favorable fusion and patient outcomes. The company says the funding will strengthen its balance sheet and support R&D and broader market reach. Accelus is headquartered in Palm Beach Gardens, Florida. Accelus develops and commercializes an ecosystem of spinal implants, instruments, biologics, and enabling technologies centered on minimally invasive surgery. Its portfolio includes the FlareHawk Interbody Fusion System with proprietary multidirectional expansion technology and the Robotic-Enabled Minimally Invasive (Remi) targeting and navigation platform. The company focuses on improving access to MIS techniques in both hospitals and ambulatory surgery centers. Accelus plans to use its recent funding to drive further adoption and commercialization of its product portfolio across the U.S. market. Led by CEO and co-founder Chris Walsh, the company aims to address clinical challenges associated with spine surgery through less disruptive implants and robotic guidance. The company is based in Palm Beach Gardens, Florida.

Total raised

$32M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jan 2024